SCYNEXIS, Inc.

LSE:0L49 Stock Report

Market Cap: US$47.1m

SCYNEXIS Valuation

Is 0L49 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0L49 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0L49 ($1.27) is trading below our estimate of fair value ($46.24)

Significantly Below Fair Value: 0L49 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0L49?

Key metric: As 0L49 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0L49. This is calculated by dividing 0L49's market cap by their current revenue.
What is 0L49's PS Ratio?
PS Ratio5.5x
SalesUS$8.57m
Market CapUS$47.06m

Price to Sales Ratio vs Peers

How does 0L49's PS Ratio compare to its peers?

The above table shows the PS ratio for 0L49 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
STX Shield Therapeutics
1.3x46.9%UK£22.7m
REDX Redx Pharma
13.9x-37.6%UK£58.3m
EAH ECO Animal Health Group
0.5x5.9%UK£44.4m
KNB Kanabo Group
5.3xn/aUK£6.0m
0L49 SCYNEXIS
5.5x30.8%US$47.1m

Price-To-Sales vs Peers: 0L49 is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does 0L49's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x5.9%US$55.67m
No more companies available in this PS range
0L49 5.5xIndustry Avg. 2.9xNo. of Companies6PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0L49 is expensive based on its Price-To-Sales Ratio (5.5x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 0L49's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0L49 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.5x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: 0L49 is expensive based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0L49 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.27
US$6.67
+424.9%
14.1%US$8.00US$6.00n/a3
Nov ’25US$1.37
US$6.67
+388.4%
14.1%US$8.00US$6.00n/a3
Oct ’25US$1.46
US$6.67
+356.6%
14.1%US$8.00US$6.00n/a3
Sep ’25US$1.42
US$6.88
+383.4%
13.0%US$8.00US$6.00n/a4
Aug ’25US$2.07
US$6.88
+232.1%
13.0%US$8.00US$6.00n/a4
Jul ’25US$1.92
US$6.88
+258.8%
13.0%US$8.00US$6.00n/a4
Jun ’25US$2.38
US$6.88
+189.2%
13.0%US$8.00US$6.00n/a4
May ’25US$1.72
US$6.88
+300.2%
13.0%US$8.00US$6.00n/a4
Apr ’25US$1.47
US$6.88
+367.7%
13.0%US$8.00US$6.00n/a4
Mar ’25US$1.64
US$7.13
+334.5%
10.4%US$8.00US$6.00n/a4
Feb ’25US$2.11
US$7.13
+237.7%
10.4%US$8.00US$6.00n/a4
Jan ’25US$2.12
US$8.13
+283.3%
14.0%US$10.00US$7.00n/a4
Dec ’24US$1.63
US$8.13
+398.5%
14.0%US$10.00US$7.00n/a4
Nov ’24US$1.88
US$9.90
+426.6%
27.2%US$15.00US$7.50US$1.375
Oct ’24US$2.29
US$9.90
+332.5%
27.2%US$15.00US$7.50US$1.465
Sep ’24US$3.75
US$11.80
+214.7%
22.4%US$15.00US$9.00US$1.425
Aug ’24US$2.89
US$11.40
+294.5%
26.4%US$15.00US$8.00US$2.075
Jul ’24US$2.93
US$11.40
+288.8%
26.4%US$15.00US$8.00US$1.925
Jun ’24US$2.54
US$11.40
+349.1%
26.4%US$15.00US$8.00US$2.385
May ’24US$3.26
US$11.40
+249.7%
26.4%US$15.00US$8.00US$1.725
Apr ’24US$2.88
US$11.20
+288.6%
28.5%US$15.00US$8.00US$1.475
Mar ’24US$1.92
US$10.60
+452.1%
34.1%US$15.00US$7.00US$1.645
Feb ’24US$1.74
US$15.00
+761.1%
54.8%US$30.00US$7.00US$2.115
Jan ’24n/a
US$15.00
0%
54.8%US$30.00US$7.00US$2.125
Dec ’23US$2.30
US$15.00
+553.2%
54.8%US$30.00US$7.00US$1.635
Nov ’23n/a
US$18.00
0%
56.5%US$30.00US$7.00US$1.885

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%